Eiger Biopharmaceuticals (NASDAQ:EIGR) was downgraded by stock analysts at ValuEngine from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Wednesday.

Several other research firms have also recently commented on EIGR. Wedbush set a $55.00 price objective on shares of Eiger Biopharmaceuticals and gave the company a “buy” rating in a research report on Friday, October 19th. Zacks Investment Research cut shares of Eiger Biopharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, October 18th. Oppenheimer set a $26.00 price objective on shares of Eiger Biopharmaceuticals and gave the company a “buy” rating in a research report on Tuesday, August 14th. Finally, LADENBURG THALM/SH SH set a $28.00 price objective on shares of Eiger Biopharmaceuticals and gave the company a “buy” rating in a research report on Wednesday, October 17th. Two research analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. Eiger Biopharmaceuticals presently has an average rating of “Buy” and an average price target of $29.71.

EIGR opened at $11.68 on Wednesday. The firm has a market capitalization of $215.01 million, a P/E ratio of -2.40 and a beta of 1.55. Eiger Biopharmaceuticals has a 12 month low of $7.46 and a 12 month high of $18.00. The company has a current ratio of 4.59, a quick ratio of 4.59 and a debt-to-equity ratio of 0.56.

Eiger Biopharmaceuticals (NASDAQ:EIGR) last posted its quarterly earnings data on Friday, November 9th. The biotechnology company reported ($1.20) EPS for the quarter, missing the consensus estimate of ($0.77) by ($0.43). As a group, equities analysts forecast that Eiger Biopharmaceuticals will post -3.29 EPS for the current year.

In other Eiger Biopharmaceuticals news, Director Eldon C. Mayer III purchased 6,000 shares of the business’s stock in a transaction on Wednesday, November 28th. The shares were purchased at an average cost of $10.07 per share, with a total value of $60,420.00. Following the transaction, the director now directly owns 7,500 shares of the company’s stock, valued at approximately $75,525. The purchase was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Eldon C. Mayer III purchased 7,500 shares of the business’s stock in a transaction on Monday, November 26th. The shares were acquired at an average cost of $9.75 per share, for a total transaction of $73,125.00. Following the completion of the transaction, the director now directly owns 7,500 shares in the company, valued at $73,125. The disclosure for this purchase can be found here. Insiders own 7.90% of the company’s stock.

Large investors have recently modified their holdings of the business. GMT Capital Corp bought a new stake in Eiger Biopharmaceuticals during the 2nd quarter worth about $3,459,000. Essex Investment Management Co. LLC bought a new stake in Eiger Biopharmaceuticals during the 3rd quarter worth about $619,000. BlackRock Inc. lifted its position in Eiger Biopharmaceuticals by 171.0% during the 2nd quarter. BlackRock Inc. now owns 219,278 shares of the biotechnology company’s stock worth $2,675,000 after buying an additional 138,366 shares in the last quarter. Acadian Asset Management LLC lifted its position in Eiger Biopharmaceuticals by 55.4% during the 3rd quarter. Acadian Asset Management LLC now owns 87,427 shares of the biotechnology company’s stock worth $1,049,000 after buying an additional 31,161 shares in the last quarter. Finally, Ardsley Advisory Partners bought a new stake in Eiger Biopharmaceuticals during the 2nd quarter worth about $305,000. 51.62% of the stock is currently owned by hedge funds and other institutional investors.

About Eiger Biopharmaceuticals

Eiger BioPharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare diseases in the United States and internationally. The company's lead program is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trial for treating hepatitis delta virus (HDV) infection.

See Also: Catch-Up Contributions

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Eiger Biopharmaceuticals (NASDAQ:EIGR)

Receive News & Ratings for Eiger Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eiger Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.